# WUXI APPTEC CO LTD-A

Summary updated: 2026-09-28T14:41:42.269621Z
Canonical: https://finbar.com/research/companies/wuxi-apptec-co-a

## Overview

WuXi AppTec Co., Ltd. is a pharmaceutical research, development and manufacturing services company serving the global pharmaceutical and life-sciences industry. Its services span drug discovery, chemistry-based drug development and manufacturing, biological discovery, preclinical testing and clinical research. The company organizes its continuing operations principally under WuXi Chemistry, WuXi Testing and WuXi Biology. [1](https://app.finbar.com/go?id=P136043041)[2](https://app.finbar.com/go?id=P136044606)

WuXi AppTec operates across Asia, Europe and North America. Its stated vision is that “every drug can be made and every disease can be treated.” In 2024, it reported revenue of approximately RMB39.24 billion, indicating the scale of its global operations. [1](https://app.finbar.com/go?id=P136043041)[3](https://app.finbar.com/go?id=P136043203)[4](https://app.finbar.com/go?id=P136043040)
[1](https://app.finbar.com/go?id=P136043041)[2](https://app.finbar.com/go?id=P136044606)[3](https://app.finbar.com/go?id=P136043203)[4](https://app.finbar.com/go?id=P136043040)

## Products & services

WuXi AppTec’s WuXi Chemistry business provides drug-discovery chemistry, process development and manufacturing services from early research through commercial production. Its work covers small-molecule drugs, oligonucleotides, peptides and related chemistry conjugates. Its TIDES business focuses on oligonucleotides and peptides; manufacturing capabilities include small-molecule active pharmaceutical ingredient production and solid-phase peptide synthesis. [5](https://app.finbar.com/go?id=P136056754)[6](https://app.finbar.com/go?id=P136054885)

WuXi Biology provides in-vitro screening and in-vivo pharmacology services, supporting target discovery, candidate selection and optimization. Its work includes nucleic acids, antibody conjugates and peptides. WuXi Testing provides chemistry, manufacturing and controls (CMC) testing, drug metabolism and pharmacokinetics (DMPK), toxicology, drug-safety evaluation and bioanalysis. [7](https://app.finbar.com/go?id=P136054733)[8](https://app.finbar.com/go?id=P136054735)[5](https://app.finbar.com/go?id=P136056754) In 2025, WuXi Chemistry generated approximately 84% of continuing-operations revenue, WuXi Testing 9% and WuXi Biology 6%; TIDES generated RMB11.37 billion, approximately 31% of Chemistry revenue. [5](https://app.finbar.com/go?id=P136056754)[9](https://app.finbar.com/go?id=P136054716)
[5](https://app.finbar.com/go?id=P136056754)[6](https://app.finbar.com/go?id=P136054885)[7](https://app.finbar.com/go?id=P136054733)[8](https://app.finbar.com/go?id=P136054735)[9](https://app.finbar.com/go?id=P136054716)

## Geographic presence

WuXi AppTec has operations across Asia, Europe and North America. Its registered office is in Wuxi, Jiangsu Province, and its principal place of business is in Shanghai. Its reported facilities include sites in Changzhou and Taixing, China, and Couvet, Switzerland; it has also reported developing sites in Middletown, United States, and Singapore. [1](https://app.finbar.com/go?id=P136043041)[10](https://app.finbar.com/go?id=P136044047)[11](https://app.finbar.com/go?id=P136043167)

In 2025, revenue from continuing operations was RMB31.25 billion from customers affiliated with the United States (72% of the total), RMB5.47 billion from China (13%), RMB4.82 billion from Europe (11%) and RMB1.88 billion from the rest of the world (4%). These figures describe customer geography, not the location of the company’s operations. [12](https://app.finbar.com/go?id=T15571837)[13](https://app.finbar.com/go?id=P136067483)
[1](https://app.finbar.com/go?id=P136043041)[10](https://app.finbar.com/go?id=P136044047)[11](https://app.finbar.com/go?id=P136043167)[12](https://app.finbar.com/go?id=T15571837)[12](https://app.finbar.com/go?id=T15571837)[12](https://app.finbar.com/go?id=T15571837)[12](https://app.finbar.com/go?id=T15571837)[12](https://app.finbar.com/go?id=T15571837)[13](https://app.finbar.com/go?id=P136067483)

## Business segments

WuXi AppTec reports four continuing-operations segments. WuXi Chemistry provides services from drug discovery and development through commercial manufacturing, including small-molecule, oligonucleotide and peptide work. WuXi Testing provides drug-development testing, including pharmacology, toxicology and bioanalysis. WuXi Biology provides research services from target discovery through candidate selection and optimization. Others comprises non-core activities and income from administrative services and materials sales. [5](https://app.finbar.com/go?id=P136056754)

In 2025, WuXi Chemistry accounted for approximately 80% of total reported revenue, WuXi Testing 9%, WuXi Biology 6% and Others 1%. The remaining approximately 4% was reported as discontinued operations, which include the WuXi ATU business and part of WuXi Testing; it is not a separate continuing-operations segment. Percentages are rounded and use total revenue, including discontinued operations, as the denominator. [14](https://app.finbar.com/go?id=T15570442)[15](https://app.finbar.com/go?id=P136056849)
[5](https://app.finbar.com/go?id=P136056754)[14](https://app.finbar.com/go?id=T15570442)[15](https://app.finbar.com/go?id=P136056849)

## Company history

WuXi AppTec traces its origins to a predecessor established in China in December 2000. Its founding individuals were Ge Li, Ning Zhao, Xiaozhong Liu and Zhaohui Zhang. The business later operated under WuXi PharmaTech, which was listed on the New York Stock Exchange. [16](https://app.finbar.com/go?id=P136027594)[17](https://app.finbar.com/go?id=P136029079)[18](https://app.finbar.com/go?id=P136028830)

WuXi AppTec Co., Ltd. was incorporated in March 2017 following the conversion of its predecessor. It listed A shares on the Shanghai Stock Exchange in May 2018 and H shares on the Hong Kong Stock Exchange in December 2018. [16](https://app.finbar.com/go?id=P136027594)
[16](https://app.finbar.com/go?id=P136027594)[17](https://app.finbar.com/go?id=P136029079)[18](https://app.finbar.com/go?id=P136028830)

## Sources

1. [WUXI APPTEC CO LTD-A — Full financial report (2024 Y), p8](https://app.finbar.com/go?id=P136043041)
2. [WUXI APPTEC CO LTD-A — Full financial report (2024 Y), p180](https://app.finbar.com/go?id=P136044606)
3. [WUXI APPTEC CO LTD-A — Full financial report (2024 Y), p33](https://app.finbar.com/go?id=P136043203)
4. [WUXI APPTEC CO LTD-A — Full financial report (2024 Y), p8](https://app.finbar.com/go?id=P136043040)
5. [WUXI APPTEC CO LTD-A — Full financial report (2025 Y), p169](https://app.finbar.com/go?id=P136056754)
6. [WUXI APPTEC CO LTD-A — Full financial report (2025 Y), p26](https://app.finbar.com/go?id=P136054885)
7. [WUXI APPTEC CO LTD-A — Full financial report (2025 Y), p11](https://app.finbar.com/go?id=P136054733)
8. [WUXI APPTEC CO LTD-A — Full financial report (2025 Y), p11](https://app.finbar.com/go?id=P136054735)
9. [WUXI APPTEC CO LTD-A — Full financial report (2025 Y), p10](https://app.finbar.com/go?id=P136054716)
10. [WUXI APPTEC CO LTD-A — Full financial report (2024 Y), p135](https://app.finbar.com/go?id=P136044047)
11. [WUXI APPTEC CO LTD-A — Full financial report (2024 Y), p27](https://app.finbar.com/go?id=P136043167)
12. [WUXI APPTEC CO LTD-A — Press release (2025 Y), p52](https://app.finbar.com/go?id=T15571837)
13. [WUXI APPTEC CO LTD-A — Press release (2025 Y), p52](https://app.finbar.com/go?id=P136067483)
14. [WUXI APPTEC CO LTD-A — Full financial report (2025 Y), p170](https://app.finbar.com/go?id=T15570442)
15. [WUXI APPTEC CO LTD-A — Full financial report (2025 Y), p179](https://app.finbar.com/go?id=P136056849)
16. [WUXI APPTEC CO LTD-A — Full financial report (2018 Y), p128](https://app.finbar.com/go?id=P136027594)
17. [WUXI APPTEC CO LTD-A — Full financial report (2018 Y), p276](https://app.finbar.com/go?id=P136029079)
18. [WUXI APPTEC CO LTD-A — Full financial report (2018 Y), p244](https://app.finbar.com/go?id=P136028830)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.